Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Assets (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Return on Assets for 6 consecutive years, with 0.55% as the latest value for Q1 2026.

  • For Q1 2026, Return on Assets fell 12.0% year-over-year to 0.55%; the TTM value through Mar 2026 reached 0.55%, down 12.0%, while the annual FY2025 figure was 0.51%, 19.0% down from the prior year.
  • Return on Assets hit 0.55% in Q1 2026 for Barinthus Biotherapeutics, up from 0.64% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.03% in Q3 2022 and bottomed at 0.64% in Q4 2025.
  • Average Return on Assets over 5 years is 0.3%, with a median of 0.33% recorded in 2023.
  • Year-over-year, Return on Assets grew 20bps in 2022 and then plummeted -36bps in 2023.
  • Barinthus Biotherapeutics' Return on Assets stood at 0.02% in 2022, then plummeted by -1795bps to 0.33% in 2023, then dropped by -6bps to 0.35% in 2024, then crashed by -83bps to 0.64% in 2025, then rose by 14bps to 0.55% in 2026.
  • According to Business Quant data, Return on Assets over the past three periods came in at 0.55%, 0.64%, and 0.64% for Q1 2026, Q4 2025, and Q3 2025 respectively.